In line with our hypothesis, GOT1 knockdown in PDA cells promoted resistance to gemcitabine and 5-FU, whereas knockdown did not similarly impact resistance to chemotherapy in the CRC lines (Fig. 4c, Additional file 1: Figure S7e). This evidence concerns the gene GOT1 and colorectal carcinoma.